Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Downey
Chromosome 17 Polysomy Without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared With Paclitaxel in Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Related publications
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Expert Opinion on Biological Therapy
Drug Discovery
Clinical Biochemistry
Pharmacology
ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway
Clinical Cancer Research
Cancer Research
Oncology
Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer
Breast Journal
Internal Medicine
Surgery
Oncology
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Investigating the Impact of Polysomy 17 in Breast Cancer Patients Without Amplification Through Meta-Analysis
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
Oncology
Hematology
Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3
European Journal of Cancer
Cancer Research
Oncology
